SJH_16-200

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
Phase III
NCT02595944
All Other|Cancer
Lung
Timothy Byun, M.D.
ECOG-ACRIN
Lavinia Dobrea
  • St. Joseph Hospital of Orange
  • xSJH Southern California